<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN" "http://jats.nlm.nih.gov/publishing/1.2/JATS-journalpublishing1.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report" dtd-version="1.2" xml:lang="en">
    <front>
        <journal-meta>
            <journal-id journal-id-type="pmc">F1000Research</journal-id>
            <journal-title-group>
                <journal-title>F1000Research</journal-title>
            </journal-title-group>
            <issn pub-type="epub">2046-1402</issn>
            <publisher>
                <publisher-name>F1000 Research Limited</publisher-name>
                <publisher-loc>London, UK</publisher-loc>
            </publisher>
        </journal-meta>
        <article-meta>
            <article-id pub-id-type="doi">10.12688/f1000research.165476.1</article-id>
            <article-categories>
                <subj-group subj-group-type="heading">
                    <subject>Case Report</subject>
                </subj-group>
                <subj-group>
                    <subject>Articles</subject>
                </subj-group>
            </article-categories>
            <title-group>
                <article-title>Case Report: Kaposi Sarcoma in Anti-Glomerular Basement Membrane Disease</article-title>
                <fn-group content-type="pub-status">
                    <fn>
                        <p>[version 1; peer review: 1 approved with reservations]</p>
                    </fn>
                </fn-group>
            </title-group>
            <contrib-group>
                <contrib contrib-type="author" corresp="yes">
                    <name>
                        <surname>Guesmi</surname>
                        <given-names>Rahma</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Conceptualization</role>
                    <role content-type="http://credit.niso.org/">Investigation</role>
                    <role content-type="http://credit.niso.org/">Methodology</role>
                    <role content-type="http://credit.niso.org/">Resources</role>
                    <role content-type="http://credit.niso.org/">Visualization</role>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Original Draft Preparation</role>
                    <uri content-type="orcid">https://orcid.org/0000-0002-1706-9181</uri>
                    <xref ref-type="corresp" rid="c1">a</xref>
                    <xref ref-type="aff" rid="a1">1</xref>
                    <xref ref-type="aff" rid="a2">2</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Boukadida</surname>
                        <given-names>Raja</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Conceptualization</role>
                    <role content-type="http://credit.niso.org/">Visualization</role>
                    <xref ref-type="aff" rid="a2">2</xref>
                    <xref ref-type="aff" rid="a3">3</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Mrabet</surname>
                        <given-names>Sanda</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Investigation</role>
                    <role content-type="http://credit.niso.org/">Supervision</role>
                    <xref ref-type="aff" rid="a2">2</xref>
                    <xref ref-type="aff" rid="a3">3</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Zellama</surname>
                        <given-names>Dorsaf</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Supervision</role>
                    <xref ref-type="aff" rid="a2">2</xref>
                    <xref ref-type="aff" rid="a3">3</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Sassi Jalleli</surname>
                        <given-names>Zohra</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Investigation</role>
                    <role content-type="http://credit.niso.org/">Supervision</role>
                    <xref ref-type="aff" rid="a1">1</xref>
                </contrib>
                <aff id="a1">
                    <label>1</label>Nephrology Department, Sidi Bouzid Regional Hospital, Sidi Bouzid, Sidi Bouzid, Tunisia</aff>
                <aff id="a2">
                    <label>2</label>Faculty of Medicine of Sousse, University of Sousse, Sousse, Sousse, Tunisia</aff>
                <aff id="a3">
                    <label>3</label>Nephrology Department, Sahloul Hospital, Sousse, Sousse, Tunisia</aff>
            </contrib-group>
            <author-notes>
                <corresp id="c1">
                    <label>a</label>
                    <email xlink:href="mailto:rahmagsm@gmail.com">rahmagsm@gmail.com</email>
                </corresp>
                <fn fn-type="conflict">
                    <p>No competing interests were disclosed.</p>
                </fn>
            </author-notes>
            <pub-date pub-type="epub">
                <day>8</day>
                <month>9</month>
                <year>2025</year>
            </pub-date>
            <pub-date pub-type="collection">
                <year>2025</year>
            </pub-date>
            <volume>14</volume>
            <elocation-id>878</elocation-id>
            <history>
                <date date-type="accepted">
                    <day>4</day>
                    <month>8</month>
                    <year>2025</year>
                </date>
            </history>
            <permissions>
                <copyright-statement>Copyright: &#x00a9; 2025 Guesmi R et al.</copyright-statement>
                <copyright-year>2025</copyright-year>
                <license xlink:href="https://creativecommons.org/licenses/by/4.0/">
                    <license-p>This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
                </license>
            </permissions>
            <self-uri content-type="pdf" xlink:href="https://f1000research.com/articles/14-878/pdf"/>
            <abstract>
                <p>Anti-glomerular basement membrane (anti-GBM) disease is a rare and life-threatening autoimmune vasculitis characterized by rapidly progressive glomerulonephritis, with or without pulmonary hemorrhage. Its management requires aggressive immunosuppressive therapy, including corticosteroids, cyclophosphamide, and plasmapheresis. Kaposi sarcoma (KS) is a vascular neoplasm linked to human herpes virus 8 (HHV-8), most frequently seen in HIV-infected or iatrogenically immunosuppressed patients. We report the case of a 39-year-old man with anti-GBM vasculitis who developed cutaneous Kaposi sarcoma two months after initiation of immunosuppressive treatment. HHV-8&#x2013;positive spindle cell proliferation was confirmed on skin biopsy. HIV testing was negative, and the lesions regressed following the tapering of corticosteroids and withdrawal of cyclophosphamide. This case highlights the importance of considering KS as a differential diagnosis in patients developing skin lesions under immunosuppressive therapy for autoimmune vasculitis.</p>
            </abstract>
            <kwd-group kwd-group-type="author">
                <kwd>Anti-glomerular basement membrane disease</kwd>
                <kwd>Kaposi sarcoma</kwd>
                <kwd>vasculitis</kwd>
                <kwd>immunosuppressive treatment</kwd>
            </kwd-group>
            <funding-group>
                <funding-statement>The author(s) declared that no grants were involved in supporting this work.</funding-statement>
            </funding-group>
        </article-meta>
    </front>
    <body>
        <sec id="sec1" sec-type="intro">
            <title>Introduction</title>
            <p>Anti-glomerular basement membrane (anti-GBM) disease, also known as Goodpasture&#x2019;s disease, is a rare but severe autoimmune vasculitis characterized by autoantibodies targeting the non-collagenous domain of the alpha-3 chain of type IV collagen (&#x03b1;3[IV]NC1) in glomerular and alveolar basement membranes.
                <sup>
                    <xref ref-type="bibr" rid="ref1">1</xref>
                </sup> It typically presents as rapidly progressive glomerulonephritis (RPGN), often accompanied by pulmonary hemorrhage, constituting the classic pulmonary&#x2013;renal syndrome.
                <sup>
                    <xref ref-type="bibr" rid="ref2">2</xref>
                </sup> The condition is life-threatening without prompt diagnosis and aggressive treatment. Standard therapy combines high-dose corticosteroids, cytotoxic agents such as cyclophosphamide, and plasmapheresis to remove circulating antibodies.
                <sup>
                    <xref ref-type="bibr" rid="ref3">3</xref>
                </sup>
            </p>
            <p>Kaposi sarcoma (KS) is an angioproliferative neoplasm associated with latent infection by human herpesvirus 8 (HHV-8). It most commonly affects individuals with acquired immunodeficiency, such as people living with HIV/AIDS or organ transplant recipients under long-term immunosuppression.
                <sup>
                    <xref ref-type="bibr" rid="ref4">4</xref>
                </sup> Iatrogenic KS can also emerge in patients receiving immunosuppressive therapy for autoimmune diseases, although this presentation remains uncommon. The cutaneous form of KS typically manifests as violaceous macules, papules, or plaques, predominantly on the lower limbs. Histologically, KS is characterized by spindle cell proliferation with neoangiogenesis and erythrocyte extravasation, and HHV-8 immunohistochemistry is diagnostic.
                <sup>
                    <xref ref-type="bibr" rid="ref5">5</xref>
                </sup>
            </p>
            <p>We report a rare case of iatrogenic Kaposi sarcoma in a patient treated for anti-GBM vasculitis. This case illustrates the potential for opportunistic neoplasms to develop in non-transplant autoimmune settings, underscoring the need for dermatologic vigilance in patients undergoing intensive immunosuppressive therapy.</p>
        </sec>
        <sec id="sec2">
            <title>Case presentation</title>
            <p>A 39-year-old man with no significant past medical history presented with gross hematuria that appeared four days after an episode of acute tonsillitis. Physical examination was unremarkable. Laboratory tests revealed acute kidney injury (serum creatinine 196 &#x03bc;mol/L), mild normocytic anemia (hemoglobin 11.9 g/dL), leukocytosis (11,800/mm
                <sup>3</sup>), and elevated C-reactive protein (CRP) at 110 mg/L. Urinalysis showed a urinary albumin/creatinine ratio of 0.5 g/g and macroscopic hematuria (600,000 red blood cells/mL), with a sterile urine culture. Abdominal ultrasound was normal.</p>
            <p>Given the presentation of glomerulonephritis without extrarenal manifestations, an immunologic workup was performed. Antinuclear antibodies and antineutrophil cytoplasmic antibodies were negative, while anti-glomerular basement membrane (anti-GBM) antibodies were strongly positive (+++). Kidney biopsy revealed extracapillary proliferation (crescent formation) in over 60% of glomeruli (9 out of 14) and acute tubular necrosis with early signs of regeneration. A chest computed tomography scan ruled out alveolar hemorrhage.</p>
            <p>The diagnosis of anti-GBM vasculitis was established, and treatment was initiated with intravenous steroid pulses followed by high-dose oral prednisone, daily oral cyclophosphamide, and a course of plasmapheresis. Despite treatment, the patient&#x2019;s renal function deteriorated, progressing to anuria and requiring initiation of hemodialysis. Anti-GBM antibodies remained positive, requiring a total of 29 plasmapheresis sessions. During hospitalization, the patient developed multiple infections, including pyelonephritis, infectious diarrhea, and esophageal candidiasis, all of which were treated with broad-spectrum antimicrobials.</p>
            <p>Approximately two months after starting immunosuppressive therapy, the patient developed violaceous skin lesions on the lower extremities (
                <xref ref-type="fig" rid="f1">
Figure 1</xref>). At that time, he was on oral cyclophosphamide and prednisone 40 mg/day. He remained otherwise asymptomatic. A skin biopsy from the left foot revealed HHV-8&#x2013;positive spindle cell vascular proliferation without vasculitis, consistent with Kaposi sarcoma (
                <xref ref-type="fig" rid="f2">
Figures 2</xref>, 
                <xref ref-type="fig" rid="f3">3</xref>, 
                <xref ref-type="fig" rid="f4">4</xref>). HIV testing was negative.</p>
            <fig fig-type="figure" id="f1" orientation="portrait" position="float">
                <label>
Figure 1. </label>
                <caption>
                    <title>Violaceous maculopapular skin lesions on the legs, suggestive of Kaposi sarcoma.</title>
                </caption>
                <graphic id="gr1" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/182115/efb5f64c-c9f9-4c73-b494-47211411e233_figure1.gif"/>
            </fig>
            <fig fig-type="figure" id="f2" orientation="portrait" position="float">
                <label>
Figure 2. </label>
                <caption>
                    <title>Hematoxylin and Eosin staining: a dermal spindle cell proliferation with hemorrhage and pigment deposition.</title>
                </caption>
                <graphic id="gr2" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/182115/efb5f64c-c9f9-4c73-b494-47211411e233_figure2.gif"/>
            </fig>
            <fig fig-type="figure" id="f3" orientation="portrait" position="float">
                <label>
Figure 3. </label>
                <caption>
                    <title>HHV-8 immunohistochemistry showing strong nuclear staining in atypical endothelial cells (x400).</title>
                </caption>
                <graphic id="gr3" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/182115/efb5f64c-c9f9-4c73-b494-47211411e233_figure3.gif"/>
            </fig>
            <fig fig-type="figure" id="f4" orientation="portrait" position="float">
                <label>
Figure 4. </label>
                <caption>
                    <title>Dense capillary proliferation in the dermis with red blood cell extravasation and spindle cells (H&amp;E).</title>
                </caption>
                <graphic id="gr4" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/182115/efb5f64c-c9f9-4c73-b494-47211411e233_figure4.gif"/>
            </fig>
            <p>Shortly afterward, the patient was admitted for upper gastrointestinal bleeding. Gastroscopy revealed actively bleeding lesions, but biopsy excluded gastrointestinal Kaposi sarcoma. The bleeding was attributed to direct oral anticoagulant, which was prescribed after arteriovenous fistula placement, and resolved with octreotide and proton pump inhibitors.</p>
            <p>In light of the Kaposi sarcoma diagnosis and absence of renal recovery, cyclophosphamide was discontinued and prednisone was rapidly tapered to 10 mg/day. The patient was referred to dermatology for follow-up but he declined further evaluation. His skin lesions regressed spontaneously over the following weeks.</p>
        </sec>
        <sec id="sec3" sec-type="discussion">
            <title>Discussion</title>
            <p>This case illustrates a rare but significant complication of immunosuppressive therapy in a patient with anti-glomerular basement membrane (anti-GBM) vasculitis. Anti-GBM disease is classically associated with rapidly progressive glomerulonephritis and pulmonary hemorrhage. Therefore,&#x00a0;its management requires aggressive immunosuppression that may predispose patients to opportunistic infections and, more rarely, virus-associated malignancies.
                <sup>
                    <xref ref-type="bibr" rid="ref1">1</xref>,
                    <xref ref-type="bibr" rid="ref2">2</xref>
                </sup>
            </p>
            <p>Kaposi sarcoma (KS) is a vascular tumor caused by human herpesvirus 8 (HHV-8), which can persist in a latent form and reactivates under immunosuppressive conditions.
                <sup>
                    <xref ref-type="bibr" rid="ref4">4</xref>
                </sup> Iatrogenic KS is typically reported in organ transplant recipients, but it may also occur in patients treated for autoimmune diseases such as systemic lupus erythematosus or vasculitis.
                <sup>
                    <xref ref-type="bibr" rid="ref6">6</xref>
                </sup> In the context of anti-GBM vasculitis, such presentations remain exceptional.</p>
            <p>Our patient developed KS two months after initiation of immunosuppressive therapy combining corticosteroids and cyclophosphamide. The diagnosis was confirmed histologically by the presence of HHV-8&#x2013;positive spindle cell vascular proliferation. The regression of skin lesions following reduction of immunosuppression supports the iatrogenic origin of the disease. He had no other recognized risk factors such as HIV infection.</p>
            <p>While the majority of iatrogenic KS cases occur in transplant medicine, the literature describes rare occurrences in autoimmune vasculitis. Tiong et al. reviewed several such cases, mostly associated with ANCA-associated vasculitis, treated with cyclophosphamide and corticosteroids.
                <sup>
                    <xref ref-type="bibr" rid="ref7">7</xref>
                </sup> The proposed mechanism involves a combination of impaired T-cell&#x2013;mediated immunity and HHV-8 reactivation.</p>
            <p>In the absence of systemic involvement, reducing or discontinuing immunosuppression is often sufficient for KS regression.
                <sup>
                    <xref ref-type="bibr" rid="ref4">4</xref>,
                    <xref ref-type="bibr" rid="ref6">6</xref>
                </sup> More advanced or visceral forms may require chemotherapy or antiviral therapy. In our case, the spontaneous regression after drug tapering and the patient&#x2019;s refusal of further dermatologic management guided a conservative approach.</p>
            <p>This case underlines the need to include KS among the differential diagnosis of skin lesions in immunosuppressed patients, even outside the context of HIV or organ transplantation. Early recognition allows timely therapeutic adjustment and may avoid unnecessary interventions.</p>
        </sec>
        <sec id="sec4" sec-type="conclusion">
            <title>Conclusion</title>
            <p>This case highlights a rare but clinically important complication of immunosuppressive therapy in anti-GBM vasculitis. Although Kaposi sarcoma is typically associated with HIV infection or solid organ transplantation, it may also occur in patients treated for autoimmune diseases. In this context, the development of cutaneous Kaposi sarcoma should prompt consideration of iatrogenic immunosuppression as a precipitating factor. Early dermatologic evaluation and timely tapering of immunosuppressive therapy can lead to spontaneous regression of lesions, as illustrated in this case. Vigilance for unusual cutaneous manifestations is therefore essential during follow-up of patients receiving potent immunosuppressive regimens.</p>
        </sec>
        <sec id="sec5">
            <title>Consent to publish</title>
            <p>A written consent to publish has been obtained from the patient.</p>
        </sec>
    </body>
    <back>
        <sec id="sec8" sec-type="data-availability">
            <title>Data availability statement</title>
            <p>No data are associated with this article.</p>
        </sec>
        <ref-list>
            <title>References</title>
            <ref id="ref1">
                <label>1</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>McAdoo</surname>
                            <given-names>SP</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Pusey</surname>
                            <given-names>CD</given-names>
                        </name>
</person-group>:
                    <article-title>Anti-Glomerular Basement Membrane Disease.</article-title>
                    <source>

                        <italic toggle="yes">Clin. J. Am. Soc. Nephrol.</italic>
</source>
                    <year>2017</year>;<volume>12</volume>(<issue>7</issue>):<fpage>1162</fpage>&#x2013;<lpage>1172</lpage>.
                    <pub-id pub-id-type="pmid">28515156</pub-id>
                    <pub-id pub-id-type="doi">10.2215/CJN.01380217</pub-id>
                    <pub-id pub-id-type="pmcid">PMC5498345</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref2">
                <label>2</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Hellmark</surname>
                            <given-names>T</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Segelmark</surname>
                            <given-names>M</given-names>
                        </name>
</person-group>:
                    <article-title>Diagnosis and classification of Goodpasture&#x2019;s disease (anti-GBM).</article-title>
                    <source>

                        <italic toggle="yes">J. Autoimmun.</italic>
</source>
                    <year>2014</year>;<volume>48-49</volume>:<fpage>108</fpage>&#x2013;<lpage>112</lpage>.
                    <pub-id pub-id-type="pmid">24456936</pub-id>
                    <pub-id pub-id-type="doi">10.1016/j.jaut.2014.01.024</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref3">
                <label>3</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Geetha</surname>
                            <given-names>D</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Jefferson</surname>
                            <given-names>JA</given-names>
                        </name>
</person-group>:
                    <article-title>ANCA-Associated Vasculitis: Core Curriculum 2020.</article-title>
                    <source>

                        <italic toggle="yes">Am. J. Kidney Dis.</italic>
</source>
                    <year>2020</year>;<volume>75</volume>(<issue>1</issue>):<fpage>124</fpage>&#x2013;<lpage>137</lpage>.
                    <pub-id pub-id-type="pmid">31358311</pub-id>
                    <pub-id pub-id-type="doi">10.1053/j.ajkd.2019.04.031</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref4">
                <label>4</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Lebb&#x00e9;</surname>
                            <given-names>C</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Kaposi sarcoma.</article-title>
                    <source>

                        <italic toggle="yes">Nat. Rev. Dis. Primers.</italic>
</source>
                    <year>2019</year>;<volume>5</volume>(<issue>1</issue>):<fpage>9</fpage>.</mixed-citation>
            </ref>
            <ref id="ref5">
                <label>5</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Pantanowitz</surname>
                            <given-names>L</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Dezube</surname>
                            <given-names>BJ</given-names>
                        </name>
</person-group>:
                    <article-title>Kaposi sarcoma in unusual locations.</article-title>
                    <source>

                        <italic toggle="yes">BMC Cancer.</italic>
</source>
                    <year>2008</year>;<volume>8</volume>:<fpage>190</fpage>.
                    <pub-id pub-id-type="pmid">18605999</pub-id>
                    <pub-id pub-id-type="doi">10.1186/1471-2407-8-190</pub-id>
                    <pub-id pub-id-type="pmcid">PMC2464778</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref6">
                <label>6</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Cattelan</surname>
                            <given-names>AM</given-names>
                        </name> 
                        <etal/>
</person-group>:
                    <article-title>Iatrogenic Kaposi&#x2019;s sarcoma in a patient with systemic lupus erythematosus.</article-title>
                    <source>

                        <italic toggle="yes">Clin. Exp. Rheumatol.</italic>
</source>
                    <year>2001</year>;<volume>19</volume>(<issue>5</issue>):<fpage>557</fpage>&#x2013;<lpage>560</lpage>.</mixed-citation>
            </ref>
            <ref id="ref7">
                <label>7</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Tiong</surname>
                            <given-names>BK</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Singh</surname>
                            <given-names>AS</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Sarantopoulos</surname>
                            <given-names>GP</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Kaposi sarcoma in anti-neutrophil cytoplasmic antibody-associated vasculitis: a case-based review.</article-title>
                    <source>

                        <italic toggle="yes">Rheumatol. Int.</italic>
</source>
                    <year>2021</year>;<volume>41</volume>(<issue>7</issue>):<fpage>1357</fpage>&#x2013;<lpage>1367</lpage>.
                    <pub-id pub-id-type="pmid">33620515</pub-id>
                    <pub-id pub-id-type="doi">10.1007/s00296-021-04810-w</pub-id>
                    <pub-id pub-id-type="pmcid">PMC8164621</pub-id>
                </mixed-citation>
            </ref>
        </ref-list>
    </back>
    <sub-article article-type="reviewer-report" id="report412840">
        <front-stub>
            <article-id pub-id-type="doi">10.5256/f1000research.182115.r412840</article-id>
            <title-group>
                <article-title>Reviewer response for version 1</article-title>
            </title-group>
            <contrib-group>
                <contrib contrib-type="author">
                    <name>
                        <surname>Jia</surname>
                        <given-names>Xiaoyu</given-names>
                    </name>
                    <xref ref-type="aff" rid="r412840a1">1</xref>
                    <role>Referee</role>
                </contrib>
                <aff id="r412840a1">
                    <label>1</label>Peking University First Hospital, Beijing, China</aff>
            </contrib-group>
            <author-notes>
                <fn fn-type="conflict">
                    <p>
                        <bold>Competing interests: </bold>No competing interests were disclosed.</p>
                </fn>
            </author-notes>
            <pub-date pub-type="epub">
                <day>16</day>
                <month>9</month>
                <year>2025</year>
            </pub-date>
            <permissions>
                <copyright-statement>Copyright: &#x00a9; 2025 Jia X</copyright-statement>
                <copyright-year>2025</copyright-year>
                <license xlink:href="https://creativecommons.org/licenses/by/4.0/">
                    <license-p>This is an open access peer review report distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
                </license>
            </permissions>
            <related-article ext-link-type="doi" id="relatedArticleReport412840" related-article-type="peer-reviewed-article" xlink:href="10.12688/f1000research.165476.1"/>
            <custom-meta-group>
                <custom-meta>
                    <meta-name>recommendation</meta-name>
                    <meta-value>approve-with-reservations</meta-value>
                </custom-meta>
            </custom-meta-group>
        </front-stub>
        <body>
            <p>The authors presented an interesting case of anti-GBM disease combined skin lesions, which was subsequently diagnosed as KS. The case is overall well written. I have the following minor comments:</p>
            <p> </p>
            <p> 1. Please provide more detailed information about the immunosuppressive treatment, including the dose of intravenous pulse corticosteroids, the dose of oral prednisone and how it was tampered during the disease course, and the cumulative dose of cyclophosphamide.&#x00a0;</p>
            <p> </p>
            <p> 2. It is interesting that this patient was not HIV positive, since there are a few case reports of HIV associated kidney diseases, including anti-GBM disease. Particularly, a proportion of the HIV patients can have positive anti-GBM antibodies, but don't develop kidney injuries. Expand a bit further the discussion on impaired T cell mediated immunity associated with KS and anti-GBM disease.</p>
            <p>Are enough details provided of any physical examination and diagnostic tests, treatment given and outcomes?</p>
            <p>Partly</p>
            <p>Is the case presented with sufficient detail to be useful for other practitioners?</p>
            <p>Yes</p>
            <p>Is sufficient discussion included of the importance of the findings and their relevance to future understanding of disease processes, diagnosis or treatment?</p>
            <p>Yes</p>
            <p>Is the background of the case&#x2019;s history and progression described in sufficient detail?</p>
            <p>Yes</p>
            <p>Reviewer Expertise:</p>
            <p>autoimmune kidney diseases</p>
            <p>I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.</p>
        </body>
    </sub-article>
</article>
